You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

DESIPRAMINE HYDROCHLORIDE - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for desipramine hydrochloride and what is the scope of patent protection?

Desipramine hydrochloride is the generic ingredient in three branded drugs marketed by Sanofi Aventis Us, Actavis Totowa, Alembic, Amneal Pharms Co, Ani Pharms, Chartwell Rx, Heritage Pharms, Novast Labs, Usl Pharma, and Validus Pharms, and is included in eighteen NDAs. Additional information is available in the individual branded drug profile pages.

There are seven drug master file entries for desipramine hydrochloride. Ten suppliers are listed for this compound.

Summary for DESIPRAMINE HYDROCHLORIDE
US Patents:0
Tradenames:3
Applicants:10
NDAs:18
Drug Master File Entries: 7
Finished Product Suppliers / Packagers: 10
Raw Ingredient (Bulk) Api Vendors: 89
Clinical Trials: 61
Patent Applications: 2,258
What excipients (inactive ingredients) are in DESIPRAMINE HYDROCHLORIDE?DESIPRAMINE HYDROCHLORIDE excipients list
DailyMed Link:DESIPRAMINE HYDROCHLORIDE at DailyMed
Recent Clinical Trials for DESIPRAMINE HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University College, LondonPhase 3
London North West Healthcare NHS TrustPhase 3
University Hospital Plymouth NHS TrustPhase 3

See all DESIPRAMINE HYDROCHLORIDE clinical trials

Pharmacology for DESIPRAMINE HYDROCHLORIDE
Medical Subject Heading (MeSH) Categories for DESIPRAMINE HYDROCHLORIDE
Anatomical Therapeutic Chemical (ATC) Classes for DESIPRAMINE HYDROCHLORIDE

US Patents and Regulatory Information for DESIPRAMINE HYDROCHLORIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Alembic DESIPRAMINE HYDROCHLORIDE desipramine hydrochloride TABLET;ORAL 209785-006 Jul 7, 2021 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Amneal Pharms Co DESIPRAMINE HYDROCHLORIDE desipramine hydrochloride TABLET;ORAL 208105-002 Mar 17, 2016 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Chartwell Rx DESIPRAMINE HYDROCHLORIDE desipramine hydrochloride TABLET;ORAL 072103-003 May 24, 1988 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for DESIPRAMINE HYDROCHLORIDE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Aventis Us PERTOFRANE desipramine hydrochloride CAPSULE;ORAL 013621-002 Approved Prior to Jan 1, 1982 ⤷  Sign Up ⤷  Sign Up
Validus Pharms NORPRAMIN desipramine hydrochloride TABLET;ORAL 014399-004 Approved Prior to Jan 1, 1982 ⤷  Sign Up ⤷  Sign Up
Sanofi Aventis Us PERTOFRANE desipramine hydrochloride CAPSULE;ORAL 013621-001 Approved Prior to Jan 1, 1982 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.